{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Desai A"],"funding":["NHLBI NIH HHS","NCI NIH HHS"],"pagination":["1054-1064"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6058768"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["103(6)"],"pubmed_abstract":["Hematopoietic stem cell transplantation following myeloablative chemotherapy is a curative treatment for many hematopoietic malignancies. However, profound granulocytopenia during the interval between transplantation and marrow recovery exposes recipients to risks of fatal infection, a significant source of transplant-associated morbidity and mortality. We have previously described the discovery of a small molecule, SW033291, that potently inhibits the prostaglandin degrading enzyme 15-PGDH, increases bone marrow prostaglandin E2, and accelerates hematopoietic recovery following murine transplant. Here we describe the efficacy of (+)-SW209415, a second-generation 15-PGDH inhibitor, in an expanded range of models relevant to human transplantation. (+)-SW209415 is 10,000-fold more soluble, p"],"journal":["Haematologica"],"pubmed_title":["A second-generation 15-PGDH inhibitor promotes bone marrow transplant recovery independently of age, transplant dose and granulocyte colony-stimulating factor support."],"pmcid":["PMC6058768"],"funding_grant_id":["U54 HL119810","R35 CA197442","P30 CA043703","K99 HL135740","P50 CA150964","R00 HL135740","R01 CA216863"],"pubmed_authors":["Dawson DM","Larusch GA","Kasturi L","Park Y","Markowitz SD","Ready JM","Zhang Y","Desai A","Gerson SL","Wald D"],"additional_accession":[]},"is_claimable":false,"name":"A second-generation 15-PGDH inhibitor promotes bone marrow transplant recovery independently of age, transplant dose and granulocyte colony-stimulating factor support.","description":"Hematopoietic stem cell transplantation following myeloablative chemotherapy is a curative treatment for many hematopoietic malignancies. However, profound granulocytopenia during the interval between transplantation and marrow recovery exposes recipients to risks of fatal infection, a significant source of transplant-associated morbidity and mortality. We have previously described the discovery of a small molecule, SW033291, that potently inhibits the prostaglandin degrading enzyme 15-PGDH, increases bone marrow prostaglandin E2, and accelerates hematopoietic recovery following murine transplant. Here we describe the efficacy of (+)-SW209415, a second-generation 15-PGDH inhibitor, in an expanded range of models relevant to human transplantation. (+)-SW209415 is 10,000-fold more soluble, p","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jun","modification":"2026-05-05T22:49:05.039Z","creation":"2019-07-25T07:07:42Z"},"accession":"S-EPMC6058768","cross_references":{"pubmed":["29472361"],"doi":["10.3324/haematol.2017.178376"]}}